Neurocrine Biosciences (NBIX) Gains from Investment Securities (2010)

Neurocrine Biosciences (NBIX) posted Gains from Investment Securities of $694000.0 for Q4 2010, up 1882.86% on a QoQ basis from $35000.0 in Q3 2010.

Neurocrine Biosciences (NBIX) Gains from Investment Securities (2010) Analysis & Trends

Neurocrine Biosciences' Gains from Investment Securities history runs 1 years deep, the most recent figure standing at $694000.0 for Q4 2010.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	88.07 Bn	86.20 Bn	-
2	Teva Pharmaceutical Industries	35.75 Bn	32.01 Bn	1.97 Bn
3	Zoetis	31.84 Bn	29.90 Bn	1.62 Bn
4	Takeda Pharmaceutical	27.18 Bn	23.12 Bn	4.39 Bn
5	United Therapeutics	23.09 Bn	20.93 Bn	648.10 Mn
6	RedHill Biopharma	21.32 Bn	21.32 Bn	-
7	Viatris	19.96 Bn	18.16 Bn	1.16 Bn
8	Neurocrine Biosciences	17.66 Bn	16.34 Bn	800.70 Mn
9	Elanco Animal Health	12.44 Bn	12.02 Bn	785.00 Mn
10	Vireo Growth	10.53 Bn	10.38 Bn	59.30 Mn

Download Data